Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS.

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease causing somatic motor neuron loss, muscle wasting, and paralysis.
• Oculomotor neurons, controlling eye movements, are uniquely spared in ALS, suggesting inherent protective mechanisms.
• Understanding these spared neurons may reveal therapeutic targets for motor neuron degeneration.

Purpose of the Study:

• To investigate the role of insulin-like growth factor 2 (IGF-2) in the resistance of oculomotor neurons in ALS.
• To explore the therapeutic potential of IGF-2 in protecting vulnerable motor neurons from degeneration in ALS and spinal muscular atrophy (SMA).

Main Methods:

• Analysis of IGF-2 and IGF-1 receptor (IGF-1R) expression in oculomotor neurons from ALS patients.
• In vitro studies using IGF-2 treatment on motor neurons derived from ALS and SMA patients.
• In vivo studies involving AAV9::IGF-2 gene delivery to muscles of SOD1(G93A) ALS mice.

Main Results:

• IGF-2 was maintained in oculomotor neurons of ALS patients, suggesting a role in their resistance.
• IGF-2 treatment protected motor neurons from ALS and SMA patient-derived cells by inducing survival pathways (Akt, GSK-3β, β-catenin).
• Gene delivery of IGF-2 in ALS mice extended lifespan by 10%, preserved motor neurons, and promoted motor axon regeneration.

Conclusions:

• Oculomotor neuron resistance in ALS is associated with maintained IGF-2 levels.
• IGF-2 exhibits neuroprotective effects against motor neuron degeneration in ALS and SMA.
• Targeting oculomotor-specific expression mechanisms can identify novel therapeutic candidates for motor neuron diseases.